scholarly journals Causes of long-term mortality in patients with head and neck squamous cell carcinomas

2021 ◽  
Author(s):  
Joan Lop ◽  
María del Prado Venegas ◽  
Albert Pujol ◽  
Blanca Sauter ◽  
Rosselin Vásquez ◽  
...  
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Causes Of Death ◽  
Second Malignancies ◽  
Age And Gender ◽  
Competing Causes ◽  
And Gender ◽  
Long Term Mortality

Abstract Purpose After treatment of a head and neck squamous cell carcinoma (HNSCC), patients with an adequate control of the tumor have a decreased overall survival when compared to age- and gender-matched controls in the general population. The aim of our study was to analyze the causes of long-term mortality in patients with HNSCC. Methods We carried out a retrospective study of 5122 patients with an index HNSCC treated at our center between 1985 and 2018. We analyzed the survival considering three causes of death: mortality associated with the HNSCC index tumor, mortality associated with a second or successive neoplasm, and mortality associated with a non-cancer cause. Results After the diagnosis of an HNSCC the most frequent cause of death is the head and neck tumor itself during the first 3.5 years of follow-up. Thereafter, mortality is more frequently associated with competing causes of death, such as second malignancies and non-cancer causes. Mortality associated with second and successive neoplasms was 2.3% per year, a percentage that was maintained constant throughout the follow-up. Likewise, mortality attributable to non-cancer causes was 1.6% per year, which also remained constant. There were differences in the mortality patterns according to the characteristics of the patients. Conclusion There are differences in the mortality patterns of patients with HNSCC depending on their characteristics. Knowledge of these patterns can help in the design of guidelines to improve the follow-up protocols of this group of patients to optimize the clinical cost-effectiveness.

scholarly journals Mortality in acromegaly: a 20-year follow-up study

2016 ◽  
Vol 23 (6) ◽  
pp. 469-480 ◽  
Author(s):  
Elina Ritvonen ◽  
Eliisa Löyttyniemi ◽  
Pia Jaatinen ◽  
Tapani Ebeling ◽  
Leena Moilanen ◽  
...  
Keyword(s):  
Causes Of Death ◽  
Age And Gender ◽  
Follow Up Study ◽  
All Cause Mortality ◽  
Long Term Follow Up ◽  
Standardized Mortality Ratios ◽  
And Gender ◽  
Causes Of Deaths

Objective It is unclear whether mortality still is increased in acromegaly and whether there are gender-related differences. We dynamically assessed outcome during long-term follow-up in our nationwide cohort. Patients and methods We studied standardized mortality ratios (SMRs) relative to the general population and causes of death in acromegaly (n=333) compared with age- and gender-matched controls (n=4995). Results During 20 (0–33) years follow-up, 113 (34%) patients (n=333, 52% women) and 1334 (27%) controls (n=4995) died (P=0.004). SMR (1.9, 95% CI: 1.53–2.34, P<0.001) and all-cause mortality (OR 1.6, 95% CI: 1.2–2.2, P<0.001) were increased in acromegaly. Overall distribution of causes of death (P<0.001) differed between patients and controls but not cardiovascular (34% vs 33%) or cancer deaths (27% vs 27%). In acromegaly, but not in controls, causes of deaths shifted from 44% cardiovascular and 28% cancer deaths during the first decade, to 23% cardiovascular and 35% cancer deaths during the next two decades. In acromegaly, cancer deaths were mostly attributed to pancreatic adenocarcinoma (n=5), breast (n=4), lung (n=3) and colon (n=3) carcinoma. In acromegaly, men were younger than women at diagnosis (median 44.5 vs 50 years, P<0.001) and death (67 vs 76 years, P=0.0015). Compared with controls, women (36% vs 25%, P<0.01), but not men (31% vs 28%, P=0.44), had increased mortality. Conclusions In acromegaly, men are younger at diagnosis and death than women. Compared with controls, mortality is increased during 20 years of follow-up, especially in women. Causes of deaths shift from predominantly cardiovascular to cancer deaths.

Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas

2001 ◽  
Vol 19 (2) ◽  
pp. 127-136 ◽  
Author(s):  
John C. Grecula ◽  
David E. Schuller ◽  
Roy Smith ◽  
Chris A. Rhoades ◽  
Subir Nag ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Regimen ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Long Term Follow Up

scholarly journals Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data

2007 ◽  
Vol 18 (11) ◽  
pp. 1856-1860 ◽  
Author(s):  
P.M. Specenier ◽  
D. Van den Weyngaert ◽  
C. Van Laer ◽  
J. Weyler ◽  
J. Van den Brande ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Feasibility Study ◽  
Phase Ii ◽  
Squamous Cell ◽  
Concurrent Radiotherapy ◽  
Long Term Follow Up

Short- and long-term mortality and causes of death after reconstruction of cancers of the head and neck with free flaps

2019 ◽  
Vol 57 (1) ◽  
pp. 21-28 ◽  
Author(s):  
S. Lahtinen ◽  
P. Koivunen ◽  
T. Ala-Kokko ◽  
O. Kaarela ◽  
P. Ohtonen ◽  
...  
Keyword(s):  
Head And Neck ◽  
Causes Of Death ◽  
Free Flaps ◽  
Short And Long Term ◽  
Long Term Mortality

Long-term toxicity following radiation therapy for head and neck squamous cell carcinoma: A retrospective study analyzing the effect of concurrent chemotherapy and advanced t-stage on late treatment-induced toxicities.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17560-e17560
Author(s):  
William Barrett ◽  
Christine Cassidy
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Late Effects ◽  
Neck Squamous Cell Carcinoma ◽  
Definitive Chemoradiation

e17560 Background: There are approximately 436,000 survivors of head and neck squamous cell carcinoma (HNSCC) in the U.S. Toxicities related to definitive chemoradiation or radiation therapy can persist for many years, with some toxicities not presenting clinically until five or more years after definitive treatment. Long-term management of late radiotherapy effects is thus warranted. Methods: This retrospective chart review has three aims: (1) comprehensively assess overall late effects of definitive radiation and chemoradiation; (2) compare treatment-related toxicities between definitive radiation and chemoradiation; and (3) compare treatment-related toxicities between patients with TNM stage T1/T2 tumors to T3/T4 tumors. Late term effects were assessed using 17 toxicity categories including xerostomia, dysphagia, and neck fibrosis. HNSCC patients included in the study were those seen by a single practitioner for follow-up of definitive radiation or chemoradiation, without a history of surgical intervention to the primary site, between June 2017 and June 2018 (N = 49). Results: The median time from the end of treatment to the most recent follow-up was 8.53 years (1.17-24.08 years). In the total cohort, the most common late effect was xerostomia (78%, N = 38), followed by dysphagia (43%, N = 21), and neck fibrosis (27%, N = 13). For the majority of toxicity categories (11 of 17), the cohort that received definitive chemoradiation had higher rates of toxicity than the cohort that received definitive radiation alone. Additionally, for the majority of toxicity categories (10 of 17), the cohort of T3/T4 tumors had higher rates of long-term toxicity than the cohort of T1/T2 tumors. Conclusions: Although the patient population in this study has excellent locoregional control after definitive radiation or chemoradiation, the majority of patients suffer from long-term treatment-related toxicities. Long-term follow up care is needed to manage the late effects of radiotherapy that can develop and persist for years after treatment completion.

scholarly journals Epilepsy-associated long-term mortality after aneurysmal subarachnoid hemorrhage

Neurology ◽  
2017 ◽  
Vol 89 (3) ◽  
pp. 263-268 ◽  
Author(s):  
Jukka Huttunen ◽  
Antti Lindgren ◽  
Mitja I. Kurki ◽  
Terhi Huttunen ◽  
Juhana Frösen ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Causes Of Death ◽  
University Hospital ◽  
Study Cohort ◽  
Catchment Population ◽  
Risk Of Death ◽  
Increased Risk ◽  
Long Term Mortality

Objective:To elucidate the epilepsy-associated causes of death and subsequent excess long-term mortality among 12-month survivors of subarachnoid hemorrhage from saccular intracranial aneurysm (SIA-SAH).Methods:The Kuopio SIA Database (kuopioneurosurgery.fi) includes all SIA-SAH patients admitted to the Kuopio University Hospital from its defined catchment population in Eastern Finland. The study cohort consists of 779 patients, admitted from 1995 to 2007, who were alive at 12 months after SIA-SAH. Their use of reimbursable antiepileptic drugs and the causes of death (ICD-10) were fused from the Finnish national registries from 1994 to 2014.Results:The 779 12-month survivors were followed up until death (n = 197) or December 31, 2014, a median of 12.0 years after SIA-SAH. Epilepsy had been diagnosed in 121 (15%) patients after SIA-SAH, and 34/121 (28%) had died at the end of follow-up, with epilepsy as the immediate cause of death in 7/34 (21%). In the 779 patients alive at 12 months after SIA-SAH, epilepsy was an independent risk factor for mortality (hazard ratio 1.8, 95% confidence interval 1.1–3.0).Conclusions:Comorbid epilepsy in 12-month survivors of SIA-SAH is associated with increased risk of death in long-term follow-up. Survivors of SIA-SAH require long-term dedicated follow-up, including identification and effective treatment of comorbid epilepsy to prevent avoidable deaths.

Abstract 19104: Impact of the Ross Procedure on Long Term Survival in Adults: A 25-year Single-center Follow-up Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Elisabeth Martin ◽  
Siamak Mohammadi ◽  
Frederic Jacques ◽  
Pierre Voisine ◽  
Daniel Doyle ◽  
...  
Keyword(s):  
General Population ◽  
Survival Rates ◽  
Ross Procedure ◽  
Term Survival ◽  
Age And Gender ◽  
Long Term Survival ◽  
Study Population ◽  
And Gender

Introduction: It has been accepted that early and mid-term survival of patients who underwent the Ross procedure is comparable to that of the general population. We reviewed our 25-year experience with the Ross procedure with the aim of defining long-term survival rates and freedom from reintervention. Hypothesis: We assessed the hypothesis that long-term survival following the Ross procedure was comparable to the general population when matched on age and gender. Methods: Between 1990 and 2015, the Ross procedure was performed on 310 consecutive adult patients in a single center. All patients were prospectively added in a dedicated cardiac surgery registry and every patient was included in the analysis. Complete postoperative clinical examination and history were obtained and transthoracic echocardiogram was performed according to a standardized protocol or when clinically indicated. There was no loss to follow-up. Median follow-up duration was 12.4 years and ranged up to 25 years. Approximately 58% of the study population was followed for more than 10 years. Results: The mean age of our cohort was 40.3 years and included 187 (60.3%) male patients. Congenital aortic valve disease was diagnosed in 77.1%. Indications for surgery were aortic stenosis in 64.6%, aortic insufficiency in 23.4% and mixed aortic disease in 12%. There were 4 (1.3%) hospital deaths and 26 (8.4%) late deaths. Survival at 10 and 25 years was 92.5% and 79.7% respectively. Freedom from pulmonary autograft reintervention was 97.5% and 48% at 10 and 25 years. Freedom from homograft-related reoperation was 99.1% and 69.9% at 10 and 25 years. Ross-related reoperation did not reduce long-term survival in our study population. However, compared to the general population, survival rate was significantly lower in patients following the Ross procedure when matched on age and gender. Conclusions: In conclusion, the Ross procedure is associated with excellent long-term survival, regardless of the need for surgical reintervention. However, long-term survival rates are lower in these patients when compared to matched individuals.

Sign in / Sign up

Export Citation Format

Share Document